Corbus Pharmaceuticals Holdings Inc
NASDAQ:CRBP
| Market Cap (Intraday) | 204.89M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.71 |
| 50-Day MA | $1.94 |
| 200-Day MA | $2.67 |
Corbus Pharmaceuticals Holdings Inc Stock, NASDAQ:CRBP
500 River Ridge Drive, Second floor, Norwood, Massachusetts 02062
United States of America
Phone: +1.617.963.0100
Number of Employees: 76
Description
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.